News and Trends 1 Sep 2022 Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose Ensysce Biosciences, Inc., a clinical-stage biotech company, and Quotient Sciences, a drug development and manufacturing accelerator, are partnering to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences is currently using […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Anti-cancer drug created from reprogrammed yeast Engineered yeast cells can synthetically produce the essential cancer medicine vinblastine, an international team of scientists showed in a new study published in Nature. In the summer and fall of 2019, some cancer patients experienced interruptions in their treatment. The reason was a shortage of the drugs vinblastine and vincristine, essential chemotherapeutic medicines for several […] August 31, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Compound found in trees has potential to kill drug-resistant bacteria Researchers say the naturally-occurring compound hydroquinine has bacterial killing activity against several microorganisms. Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a […] August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Researchers identify possible target for type of sporadic ALS Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Swiss biotech […] August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 United BioPharma gets FDA approval for phase 2 HIV drug trial Taiwan-headquartered United BioPharma (UBP) says the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of the study is to assess the safety and antiviral activity of UB-421 in combination with optimized background ART […] August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Emactuzumab designated as an orphan medicinal product for TGCT in Europe SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal product for both localized and diffuse types of the disease by the European Medicines Agency (EMA). No systemic treatments have been approved for TGCT in […] August 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Laverock Therapeutics created to develop next generation of programmable cell therapies Laverock Therapeutics Ltd has been founded to develop a gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the U.K. company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of its senior management team. Laverock Therapeutics started out […] August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS Peer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis […] August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Vilya emerges to target disease biology VILYA, Inc. (Vilya), a biotech company aiming to create a new class of medicines to precisely target disease biology, launched today. Vilya is co-founded by scientists from the Institute of Protein Design (IPD) led by David Baker, and ARCH Venture Partners. The company’s platform, powered by advanced machine learning, taps into uncharted chemical space to […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine Grid Biosciences has signed a license agreement for the development of a vaccine against Epstein-Barr virus (EBV) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The agreement includes access to NIH’s patent rights in EBV envelope proteins that the virus uses to gain entry into […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 PharmAla Biotech files patent applications for MDMA analogs Canadian company PharmAla Biotech has filed a key patent cooperation treaty (PCT) application, containing six novel chemical entities (NCEs). The application claims priority to, and benefit of a United States provisional patent application filed August 20, 2021. The PCT application disclosed novel compositions of MDMA and analogs that may be used to alleviate the known […] August 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Malaysian Genomics and Ajlan to explore MENA biopharma opportunities Malaysian Genomics Resource Centre Berhad, a genomics and biopharmaceutical company, has signed a memorandum of understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company. Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email